EVALUATION OF THE EFFECTIVNESS OF COMBINATION THERAPY WITH LIRAGLUTIDE AND ANTIOXIDANTS ON THE COURSE OF TYPE 1 DIABETES MELLITUS
Diabetes mellitus is a chronic non-infectious disease which morbidity rate has increased and reached epidemic proportions. The IDF Diabetes Atlas is the authoritative resource on the global impact of diabetes. First published in 2000, it is produced by the International Diabetes Federation (IDF) in collaboration with a committee of scientific experts from around the world and contains statistics on diabetes prevalence, diabetes-related mortality and health expenditure at the global, regional and national level. The latest data published in the IDF Diabetes Atlas 9th edition shows that 463 million adults are currently living with diabetes. β-cells takes an integral role in pathogenesis of this disease. This article presents research information about effect of combination therapy of liraglutide and antioxidant for course of 1 diabetes mellitus type. 10 human who were affected by 1 type of diabetes mellitus for eight years and had clinical laboratory remission for four years which had became three months after manifestation were investigated. Course of diabetes is without episodes of metabolic decompensation and diagnosis of macro- and micro- vasal complications. C-peptide and glycosylated hemoglobin have been used as core measures, after 1 month of treatment of which, indicators shown a positive dynamic. This type of therapy can become foundation for new methods of treatment of 1 type of diabetes mellitus which does not include cytokine secretion patterns.